Kamada (KMDA) Reports Q1 Loss of $0.11/Share; Reaffirms FY Rev. Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Kamada Reports 2017 First Quarter Financial Results
May 16, 2017 7:00 AM EDTReaffirms revenue guidance of $100 million for 2017
Proprietary Products segment for 2017 projected at $76-$78 million, up at least 36% compared to 2016
Conference call today at 8:30 am Eastern Time
NESS ZIONA, Israel, May 16, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. Â (Nasdaq: KMDA) (TASE:KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced financial results for the first quarter ended March 31, 2017.Â
Our first quarter revenues were impacted by a delay in completing a periodic validation of our... More
